Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.70 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.43 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.43 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TACR3 | P29371 | 5/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2432144 | 1.00 | CTSB (0.70) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2432156 | 1.00 | CTSB (0.70) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2432160 | 1.00 | CTSB (0.70) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2425065 | 0.99 | CTSB (0.71) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2431706 | 0.99 | CTSB (0.71) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2431712 | 0.99 | CTSB (0.71) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL13335467 | 0.99 | CTSB (0.71) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL7928661 | 0.92 | CTSB (0.70) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12325244 | 0.91 | CTSB (0.57) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8238289 | 0.91 | CTSB (0.57) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-8754105-B2 | Macrocyclic inhibitors of hepatitis C virus | MEDIVIR AB (SE) | 2014-06-17 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | JANSSEN SCIENCES IRELAND UC (IE) | 2011-09-29 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | TIBOTEC PHARMACEUTICALS LTD. | 2010-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120855-A1 | MACROCYLIC INHIBITORS OF HEPATITIS C VIRUS | NR4A1, NR4A3, NR4A2 | CTSB 4085/4885CTSS 3833/4885ADRB3 1217/4885 |
| US-20110237621-A1 | Macrocyclic Inhibitors of Hepatitis C Virus | NR4A1, NR4A3, NR4A2 | CTSB 4294/4885CTSS 3996/4885ADRB3 1031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.